Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED (China) Limited has called its 2026 annual general meeting for May 12, 2026 in Hong Kong as a hybrid event with both physical and electronic participation options for shareholders. The agenda includes adoption of the 2025 audited financial statements, re-election of directors, and re-appointment of PricewaterhouseCoopers entities as independent auditors for Hong Kong and U.S. financial reporting.
Shareholders will also vote on a special resolution granting the board a general mandate to issue up to 10% of the company’s existing share capital, subject to pricing limits tied to recent market prices. In addition, an ordinary resolution will authorize the company to repurchase its shares or related depositary interests across its listings on AIM, NASDAQ and the Hong Kong Stock Exchange, enhancing financial flexibility and capital management options for the board.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$23.50 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies, with its shares listed in Hong Kong, London and on NASDAQ, giving it access to multiple international capital markets.
Average Trading Volume: 4,707,832
Technical Sentiment Signal: Sell
Current Market Cap: HK$20.29B
For an in-depth examination of 0013 stock, go to TipRanks’ Overview page.